Today: 22 May 2026
Apex Critical Metals stock slips on Rift rare earth drill update — the next catalyst is close
19 January 2026
1 min read

Apex Critical Metals stock slips on Rift rare earth drill update — the next catalyst is close

Toronto, January 19, 2026, 13:02 EST — Regular session

  • Apex Critical Metals shares dropped 9.7%, slipping to C$3.26 by midday.
  • The explorer announced plans for an 8,000-metre Phase I drilling campaign at its Rift Rare Earth Project in Nebraska.
  • Investors are eyeing fresh spending focused on developing rare-earth magnet supply chains beyond China.

Shares of Apex Critical Metals (CSE:APXC; OTCQX:APXCF) dropped 9.7% to C$3.26 on Monday, reversing some of their recent rally as the company outlined plans for its Rift Rare Earth Project in Nebraska.

Timing is crucial. Rare earths, a set of 17 elements, are embedded in permanent magnets found in electric motors and defence equipment, prompting Western manufacturers to rush securing their supply chains.

Money is flowing downstream as well. U.S. magnet maker Noveon Magnetics announced it has closed a $215 million Series C round led by One Investment Management, aiming to boost domestic production. CEO Scott Dunn said the funding will help “scale” output to keep up with “rapidly growing customer demand.” PR Newswire

Apex, still in the early stages, is gearing up for Phase I drilling that “contemplates 8,000 m of coring across 10 to 15 drill holes,” targeting depths between 600 and 900 metres. CEO Sean Charland described the company as “in an outstanding position” ahead of the drilling start. Assay results are anticipated in the first half of 2026. MINING.COM

The program aims to confirm and build on historical intersections from previous campaigns. Step-out holes are scheduled to the north and south, targeting a larger geophysical anomaly, the company said.

Monday’s selloff underscored just how volatile this trade can be. The stock has surged over the past year, but thin volume often magnifies swings—especially as investors attempt to value an exploration story ahead of any solid drill results.

The obvious downside is there too. If assays come back weak, drilling drags on, or funding dries up, small-cap explorers can see their valuations drop fast—and often with little notice.

Apex isn’t the only player pushing a North American rare-earth story, but it’s ahead of the bigger names in production and development. That carries risks: it’s less proven, yet also reacts more sharply to each new piece of data.

Traders are eyeing a clear next step: when the rigs start moving and what the initial assays reveal. Apex expects to deliver results in the first half of 2026.

Stock Market Today

  • NYSE's Martin Questions Nasdaq Rules Attracting SpaceX IPO
    May 22, 2026, 9:22 AM EDT. Lynn Martin, President of the New York Stock Exchange (NYSE), criticized some of the Nasdaq's listing rules used to attract SpaceX's public offering as "questionable." Speaking on Bloomberg Surveillance, Martin emphasized that market integrity should not be compromised for competitive gains between stock exchanges. She noted 2023 has been a strong year for initial public offerings (IPOs) across sectors and affirmed the NYSE's commitment to bringing more companies public. Martin's remarks highlight ongoing debates over regulatory standards and competitive practices in the IPO market.

Latest articles

Akari Therapeutics Stock Is Soaring Again — The KRAS Cancer Data Behind the Move

Akari Therapeutics Stock Is Soaring Again — The KRAS Cancer Data Behind the Move

22 May 2026
Akari Therapeutics shares more than doubled in premarket trading Friday after its lead cancer drug showed positive preclinical results in KRAS-mutated pancreatic cancer models and the company announced a $5.5 million private placement. The stock was quoted at $10.15, up from Thursday’s $5.14 close. Akari plans to start Phase 1 human trials of AKTX-101 by mid-2027. The company reported $2.8 million in cash at March 31.
BMO Lands Buy Rating Ahead of Earnings But Targets Raise Questions

BMO Lands Buy Rating Ahead of Earnings But Targets Raise Questions

22 May 2026
Canaccord Genuity reaffirmed a Buy rating on Bank of Montreal ahead of its May 27 earnings report. BMO shares closed May 21 at C$220.06, near a 52-week high and up 23.5% year-to-date. The bank recently agreed to sell C$14.5 billion in loan and lease assets to Stonepeak, expecting a CET1 ratio boost but a C$900 million after-tax charge. Analyst consensus remains mixed, with most holding or selling.
Atmos Energy’s run in Texas faces new Wall Street target cut

Atmos Energy’s run in Texas faces new Wall Street target cut

22 May 2026
Morgan Stanley lowered its Atmos Energy price target to $183 from $195, maintaining an Equalweight rating. The move follows Atmos’ recent increase in its 2026 earnings outlook and annual dividend. Atmos shares closed at $177.46 on Thursday. Texas remains central to Atmos’ growth and regulatory strategy, with 65% of its rate base in the state.
AI stocks brace for tariff shock as Nvidia, Microsoft slide in Europe ahead of Wall Street return
Previous Story

AI stocks brace for tariff shock as Nvidia, Microsoft slide in Europe ahead of Wall Street return

Nestle stock price falls in Zurich on tariff jitters; what investors watch before Feb. 19 results
Next Story

Nestle stock price falls in Zurich on tariff jitters; what investors watch before Feb. 19 results

Go toTop